TRVI
NASDAQTrevi Therapeutics Inc.
Trevi Therapeutics Inc. (TRVI) is a Biotechnology: Pharmaceutical Preparations company listed on NASDAQ. In the last 30 days Quantisnow tracked 3 wire items for TRVI, including 2 press releases and news items and 1 earnings update. The most recent was published Nov 2, 2026.
TRVI rankings
Financial highlights
Full financials- Net income, TTM
- -$51.11M
- Free cash flow, TTM
- -$52.87M
- Cash
- $54.30M
For the twelve months ended Jun 30, 2026, from SEC filings. Not investment advice.
News · 26 weeks22+50%
2026-05-102026-11-01
Mix790d
- Other4(57%)
- SEC Filings1(14%)
- Insider1(14%)
- Earnings1(14%)
Latest news
25 items- PRTrevi Therapeutics to Report Third Quarter 2026 Financial Results and Provide a Corporate Update on November 9, 2026NEW HAVEN, Conn., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that senior management will host a conference call and live audio webcast on Monday, November 9, 2026, at 4:30 p.m. ET, to provide a corporate update and review the Company's financial results for the quarter ended September 30, 2026. Conference Call and WebcastTo register for the live conference call
- PRTrevi Therapeutics to Participate in Stifel's 2026 Healthcare ConferenceNEW HAVEN, Conn., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that Jennifer Good, President and Chief Executive Officer, and David Hastings, Chief Financial Officer, will participate in a fireside chat at the Stifel 2026 Healthcare Conference on Wednesday, November 11, at 10:00 a.m. ET. The conference will be held from November 10-12 in New York, and Ms. Good and
- PRTrevi Therapeutics Announces Oral Presentation Accepted at the CHEST 2026 Annual MeetingNEW HAVEN, Conn., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy oral nalbuphine ER for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that results from the Phase 2b CORAL trial were accepted as an oral presentation at the CHEST 2026 Annual Meeting of the American College of Chest Physicians, taking place from October 18 – 21, 2026, in Phoenix, Arizona. Abstract: Patient-Reported Outcomes Show Early and Sustained Improvement Following Nalbuphine
- INSIDERDirector Heffernan Michael Thomas exercised 39,473 shares at a strike of $3.19 and sold $595,806 worth of shares (39,473 units at $15.09) as part of a pre-agreed trading plan (SEC Form 4)4 - Trevi Therapeutics, Inc. (0001563880) (Issuer)
- SECSEC Form 144 filed by Trevi Therapeutics Inc.144 - Trevi Therapeutics, Inc. (0001563880) (Subject)
- PRTrevi Therapeutics to Participate in Upcoming September ConferencesNEW HAVEN, Conn., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that senior management will participate in the following conferences in September. 2026 Cantor Global Healthcare ConferenceSeptember 9-11, 2026, New York, New YorkFireside Chat: September 10, 10:55 a.m. to 11:25 a.m. ETTrevi Representatives: Jennifer Good, President and CEO, and David Hastings, CFOTo
- PRTrevi Therapeutics Announces Upcoming Presentations at the European Respiratory Society (ERS) Congress 2026Professor Marlies Wijsenbeek will give an oral presentation on the quality-of-life outcomes assessed by the LCQ from the Phase 2b CORAL trial of nalbuphine ER for the treatment of patients with IPF-related chronic cough Dr. Imran Satia will give a poster presentation on the quality-of-life outcomes assessed by the LCQ from the Phase 2a RIVER trial of nalbuphine ER for the treatment of patients with RCC NEW HAVEN, Conn., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy oral nalbuphine ER for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF
- SECSEC Form S-8 filed by Trevi Therapeutics Inc.S-8 - Trevi Therapeutics, Inc. (0001563880) (Filer)
- SECSEC Form 10-Q filed by Trevi Therapeutics Inc.10-Q - Trevi Therapeutics, Inc. (0001563880) (Filer)
- SECTrevi Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Trevi Therapeutics, Inc. (0001563880) (Filer)
- PRTrevi Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business UpdatesInitiated Phase 3 OCEAN-1 trial for patients with idiopathic pulmonary fibrosis-related chronic cough in the second quarter; Phase 3 OCEAN-2 trial expected to initiate in the third quarter of 2026 Initiated Phase 2b LAKE trial for patients with refractory chronic cough in the second quarter; sample size re-estimation expected in the fourth quarter of 2026 Management to host a conference call and webcast today at 4:30 p.m. ET NEW HAVEN, Conn., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathi
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Trevi Therapeutics Inc.SCHEDULE 13G/A - Trevi Therapeutics, Inc. (0001563880) (Subject)
- PRTrevi Therapeutics to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 6, 2026NEW HAVEN, Conn., July 30, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that senior management will host a conference call and live audio webcast on Thursday, August 6, 2026, at 4:30 p.m. ET, to provide a corporate update and review the Company's financial results for the quarter ended June 30, 2026. Conference Call and WebcastTo register for the live conference call and
- PRTrevi Therapeutics to Participate in Upcoming August ConferencesNEW HAVEN, Conn., July 28, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that senior management will participate in the following conferences in August. Oppenheimer's Biotech in the Berkshires August 4, 2026, Berkshires, MassachusettsTrevi Representative: Jennifer Good, President and CEO Stifel's 2026 Biotech Summer SummitAugust 10-12, 2026, Newport, Rhode IslandFireside C
- ANALYSTBMO Capital Markets initiated coverage on Trevi Therapeutics with a new price targetBMO Capital Markets initiated coverage of Trevi Therapeutics with a rating of Outperform and set a new price target of $36.00
- PRTrevi Therapeutics Announces Upcoming June and July Event ScheduleNEW HAVEN, Conn., June 17, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that senior management will attend several upcoming events in June and July. BIO International Convention June 22-25, 2026, San Diego, CaliforniaTrevi Representatives: Jennifer Good, President and CEO, and Farrell Simon, Pharm.D., CCO Leerink Partners Therapeutics Forum 2026July 14-15, 2026, Bosto
- INSIDERSEC Form 4 filed by Director Mathers Edward T4 - Trevi Therapeutics, Inc. (0001563880) (Issuer)
- SECTrevi Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - Trevi Therapeutics, Inc. (0001563880) (Filer)
- INSIDERSEC Form 4 filed by Director Colangelo Dominick4 - Trevi Therapeutics, Inc. (0001563880) (Issuer)
- INSIDERSEC Form 4 filed by Director Vanlent Anne4 - Trevi Therapeutics, Inc. (0001563880) (Issuer)
- INSIDERSEC Form 4 filed by Director Heffernan Michael Thomas4 - Trevi Therapeutics, Inc. (0001563880) (Issuer)
- INSIDERSEC Form 4 filed by Director Meeker David P4 - Trevi Therapeutics, Inc. (0001563880) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Trevi Therapeutics Inc.SCHEDULE 13G/A - Trevi Therapeutics, Inc. (0001563880) (Subject)
- SECSEC Form 10-Q filed by Trevi Therapeutics Inc.10-Q - Trevi Therapeutics, Inc. (0001563880) (Filer)
- SECTrevi Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Trevi Therapeutics, Inc. (0001563880) (Filer)
TRVI FAQ
10 questionsWhat does Trevi Therapeutics Inc. do?
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, which is in Phase IIb/III clinical trial is an oral extended release formulation of nalbuphine that is used for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson's disease, as well as to treat chronic kidney disease-associated with pruritus. It has a license agreement with...What is the latest news on TRVI?
In the last 30 days Quantisnow tracked 3 wire items for TRVI: 2 press releases and news items and 1 earnings update. The most recent was published on November 2, 2026.Is TRVI profitable?
No. Trevi Therapeutics Inc. reported a net loss of $51.11M for the twelve months ended Jun 30, 2026.How much cash and debt does TRVI have?
Trevi Therapeutics Inc. reported $54.30M in cash and cash equivalents on its most recent balance sheet in SEC filings.Where does TRVI stock trade?
Trevi Therapeutics Inc. (TRVI) is listed on NASDAQ.What sector and industry is TRVI in?
Trevi Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Trevi Therapeutics Inc. go public?
Trevi Therapeutics Inc. (TRVI) completed its IPO in 2019.What are analysts saying about TRVI?
Across the last 8 analyst actions on Trevi Therapeutics Inc., there was 1 upgrade and 0 downgrades. The most recent action was from BMO Capital Markets: Outperform with a $36.00 price target on 2026-07-21. Recent price targets range from $7.50 to $36.00.What companies are similar to TRVI?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare TRVI side-by-side with any of them on Quantisnow.How can I track TRVI on Quantisnow?
Quantisnow aggregates Trevi Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow TRVI to receive live email and push alerts on every new disclosure.